Biolife Solutions INC Form 4 insider transactions

Catherine Coste, a Director at BioLife Solutions Inc., was granted 8,170 shares of common stock as part of the company's 2023 Performance Incentive Plan.

BioLife Solutions Director Rachel Ellingson acquired 8,170 shares of common stock as part of the company's 2023 Performance Incentive Plan.

BioLife Solutions Inc. CEO Roderick de Greef acquired over 500,000 shares through restricted stock awards, demonstrating strong performance-based vesting.

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, reported the acquisition of restricted stock awards and a related tax withholding transaction.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, vested 23,548 performance-based restricted stock units and subsequently sold 5,734 shares to cover tax obligations.

BioLife Solutions' Chief Technology Officer, Sean Werner, was granted 24,116 shares of common stock as part of his 2026 compensation, vesting over four years.

BioLife Solutions director Timothy L. Moore acquired 8,170 shares of common stock as restricted stock under the company's 2023 Performance Incentive Plan.

BioLife Solutions' Chief Quality and Operations, Karen A. Foster, reported the vesting of restricted stock and subsequent tax-related share withholding.

Joydeep Goswami, a Director at BioLife Solutions Inc., acquired 8,170 shares of common stock through a restricted stock grant.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 990 shares of common stock at $25.59 per share to cover tax withholding obligations.

BioLife Solutions' Chief Quality and Operations, Karen A. Foster, sold 335 shares of common stock to cover tax withholding obligations.

BIOLIFE SOLUTIONS Chief Human Resources Officer, Sarah Aebersold, sold 241 shares of common stock to cover tax withholding obligations.

BioLife Solutions' EVP and Chief Scientific Officer, Aby J. Mathew, sold 405 shares of common stock to cover tax withholding obligations.

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 344 shares of common stock to cover tax withholding obligations related to restricted stock vesting.

Aby J. Mathew, EVP & Chief Scientific Officer at BioLife Solutions Inc., sold 631 shares of common stock to satisfy tax withholding obligations.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 1,033 shares of common stock to cover tax withholding obligations.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, sold 946 shares of common stock in December 2025 to satisfy tax withholding obligations from restricted stock vesting.

BIOLIFE SOLUTIONS Director Amy DuRoss reported a pre-scheduled sale of 2,000 common stock shares at $24.6 each.

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 358 shares of common stock at $25.13 per share to cover tax withholding obligations related to restricted stock vesting.

BioLife Solutions' Chief Quality and Operations, Karen A. Foster, sold 519 shares of common stock to cover tax withholding obligations.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 30,000 shares of common stock for approximately $25.72 per share under a pre-arranged trading plan.

BioLife Solutions Director Amy DuRoss sold 4,000 shares of common stock for $108,000 through a pre-arranged trading plan.

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 351 shares of common stock to cover tax withholding obligations from restricted stock vesting.

BioLife Solutions CFO Troy Wichterman sold 584 shares of common stock for $26.74 per share to cover tax withholding obligations.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, sold 217 shares of common stock for $26.74 per share to cover tax withholding obligations.

BioLife Solutions' Chief Quality and Operations, Karen A. Foster, sold 415 shares of common stock for tax withholding purposes.

BioLife Solutions' Chief Technology Officer, Sean Werner, sold 110 shares of common stock for $26.74 per share to cover tax withholding obligations under a pre-arranged 10b5-1 plan.

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, sold 526 shares of common stock to cover tax withholding obligations related to restricted stock vesting.

BioLife Solutions Director Amy DuRoss reported selling 6,000 shares of common stock over three days in November 2025.

BioLife Solutions' President and CEO, Roderick De Greef, reported the sale of 100,000 shares of common stock in multiple transactions under a pre-arranged Rule 10b5-1 trading plan.